CompletedPhase 2NCT02824718
Recombinant Human rhPTH(1-34) VS Association Alfacalcidol/Hydrochlorothiazide in Severe Primary Hypoparathyroidism
Studying Autosomal dominant hypocalcemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Assistance Publique - Hôpitaux de Paris
- Principal Investigator
- Anne Blanchard, MD, PhDAssistance Publique - Hôpitaux de Paris
- Intervention
- Teriparatide(drug)
- Enrollment
- 16 enrolled
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2017 – 2020
Study locations (1)
- AP-HP Hopital Europeen Georges Pompidou, Paris, France
Collaborators
Ministry of Health, France
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02824718 on ClinicalTrials.govOther trials for Autosomal dominant hypocalcemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07428057Postoperative Hypocalcemia After ThyroidectomyMinia University
- RECRUITINGPHASE2, PHASE3NCT07080385Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)Calcilytix Therapeutics, Inc., a BridgeBio company
- ACTIVE NOT RECRUITINGPHASE3NCT05680818Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1Calcilytix Therapeutics, Inc., a BridgeBio company
- ACTIVE NOT RECRUITINGNCT05227287ADH1 and ADH2 Disease Monitoring Study (DMS)Calcilytix Therapeutics, Inc., a BridgeBio company